BPC-157 vs TB-500: the two halves of the 'Wolverine Stack' compared
Two research peptides routinely marketed for injury recovery. Different mechanisms, overlapping hype, similarly thin human evidence. Here's what each actually has going for it.
BPC-157 and TB-500 are the two most widely-marketed research peptides for injury recovery — the components of the 'Wolverine Stack' referenced throughout biohacker forums and sports-adjacent content. Both are on the FDA's Category 2 list (research-use-only, not legally compoundable in the US) with a February 2026 HHS proposed removal. Neither is FDA approved. Both have substantial preclinical animal data and minimal rigorous human trial evidence.
| Field | BPC-157 | TB-500 |
|---|---|---|
| Brand names | Body Protection Compound, PL 14736 | Thymosin Beta-4 fragment |
| Manufacturer | Synthetic (various research vendors) | Synthetic (various research vendors) |
| FDA approved | Not FDA approved; Category 2 (Sep 2023); Feb 2026 HHS proposed removal | Not FDA approved; Category 2 (Sep 2023); Feb 2026 HHS proposed removal |
| Indication | Research: tissue repair, GI protection | Research: tissue repair, wound healing |
| Mechanism | Proposed: VEGF upregulation, nitric oxide modulation, FAK/paxillin pathway, dopamine/serotonin modulation | Derived from Tβ4; actin sequestration, angiogenesis promotion, anti-inflammatory |
| Delivery | Research-use injection or oral (not for human use) | Research-use injection (not for human use) |
Primary sources
- BPC-157: BPC-157 narrative review (PMC, 2025)
Frequently asked
Which one has more evidence?
BPC-157 has the larger preclinical (animal model) corpus but most of that research originates from a single Croatian research group. TB-500's parent protein (thymosin beta-4) has more independent research lines including some Phase 2 clinical exposure via RegeneRx. Neither fragment has Phase 3 human trial evidence.
Is the 'Wolverine Stack' (BPC-157 + TB-500) effective?
There is no randomized controlled trial evidence for the combination. Anecdotal reports in biohacker communities cannot substitute for clinical evidence. The combination's marketing substantially outruns the data.
Are either legal in the US right now?
Both are FDA Category 2 (cannot be compounded under 503A or 503B), and neither is FDA approved. Research-peptide vendors sell them with 'research use only' labeling, which the FDA has stated is void when paired with dosing information or therapeutic claims. Several vendors received warning letters in December 2024.
What might change in 2026?
The February 2026 HHS proposal to remove 14 peptides (including both BPC-157 and TB-500) from Category 2 could restore legal compounding access if the FDA ratifies the proposal after PCAC review. That ruling is expected post the July 2026 advisory committee hearing.